GNPNAT1

Across TCGA pan-cancer cohorts, GNPNAT1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GNPNAT1 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher GNPNAT1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated GNPNAT1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

LUAD, GBM, and PDAC are the cancer types where GNPNAT1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	All	0.574	0.903	<.001	38	view →
GBM	OS	Tertile	All	0.376	0.626	.001	23	view →
PDAC	OS	Tertile	III,IV	0.977	0.552	.011	9	view →
UCEC	DFS	Quartile	II,III,IV	1.000	0.430	.011	8	view →
HNSC	DFS	Tertile	All	0.623	1.000	.040	6	view →
CCRCC	OS	Quartile	II,III,IV	0.585	0.930	.019	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

GNPNAT1–LUAD (OS)

Open the LUAD breakdown →